Vesicle Therapeutics Inc.
The University of Colorado Connection
Vesicle Therapeutics is a Longmont-based biotechnology company developing programmable extracellular vesicles, known as “gectosomes,” to deliver macromolecular therapeutics to intracellular targets. Founded by (鶹ѰBoulder Biochemistry), the company builds upon research from his lab focused on engineering vesicles for targeted delivery. Gectosomes are designed to encapsulate therapeutic proteins and nucleic acids, facilitating their delivery into cells and enabling applications such as genome editing and treatment of diseases like cancer and neurodegeneration. Vesicle Therapeutics has received National Institutes of Health (NIH) SBIR and STTR funding to advance its platform, including projects targeting familial hypercholesterolemia and neurodegenerative diseases.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Round: Seed
- Contact for Investment Inquiries: , curtis.woodard@vesicletherapeutics.com
In the News
Technology Development Funding
U.S. National Institutes of Health (NIH)
This page was last updated on May 19, 2026. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor eNewsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard,senior marketing and communications specialist for Venture Partners at 鶹ѰBoulder.
For media inquiries, please visit .